January 27 - 30, 2018
JW Marriott Austin
Austin, Texas, USA
Abstract submission deadline: Friday, November 10
Advance registration deadline: Friday, December 15
Welcome RemarksConference Cochairs
Plenary Session 1: Global Obesity BurdenSession Chair: Elizabeth A. Platz, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland5:45-7 p.m.
Interpreting literature evidence on obesity and cancer Konstantinos K. Tsilidis, University of Ioannina School of Medicine, Ioannina, Greece
Global Burden of Cancer Attributable to Excess Body Weight Andrew Renehan, University of Manchester, Manchester, United Kingdom
Estimating the current and future cancer burden attributable to obesity in Canada* Darren Brenner, University of Calgary, Calgary, AB, Canada
Opening Reception7-9 p.m.
Sunday, Jan. 28Continental Breakfast
Plenary Session 2:
Insulin and Glycemia: Roles in Obesity and CancerSession Chair: Michael N. Pollak, McGill University, Montreal, QC, Canada8-10 a.m.
Mechanisms of lipid-induced insulin resistance: Implications for obesity and cancer Gerald Shulman, Yale University, New Caven, Connecticut
Insulin responsivity of cancer subsets Michael N. Pollak
Obesity, hyperglycemia, and cancer in black and white adultsCorinne E. Joshu, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland
Circumventing insulin feedback increases PI3K inhibitor efficacy*Benjamin Hopkins, Weill Cornell Medicine, New York, New York
Plenary Session 3: Inflammation as a Consequence of ObesitySession Chair: Andrew J. Dannenberg, Weill Medical College of Cornell University, New York, New York10:15-12:00 p.m.
Breast adipose inflammation: A silent killer Andrew J. Dannenberg
Understanding the differential role of white and brown adipocytes in cancer: depicting the mechanisms linkingobesity and cancer Kelly Grace Magalhaes, Univeristy of Brasília, Brasília, Brazil
Metformin decreases obesity-associated macrophage infiltration and lymphangiogenesis in the tumor microenvironment in a rodent model of breast cancer*Erin Giles, Texas A&M University, College Station, Texas
Reversing the procancer effects of obesity in a mouse model of colon cancer: Diet versus drug*Laura Bowers, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
Obesity and breast cancer metastasis: The role of inflammation* Shannon McDonell, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
Poster Session A/Lunch12:00-2:15 p.m.
Plenary Session 4: Site-Specific Cancers part 1Session Chair: Lorelei Mucci, Harvard T.H. Chan School of Public Health, Boston, Massachusetts2:15-4:15 p.m.
Title to be announced Matthew G. Vander Heiden, David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, Massachusetts
Exploring mechanisms underlying the link between obesity and lethal prostate cancer Lorelei Mucci
Body weight and weight change over the life course and subsequent risk of breast cancer Susan E. Hankinson, University of Massachusetts Amherst, Amherst, Massachusetts
Body fat and risk of breast cancer in normal-size postmenopausal women*Neil Iyengar, Memorial Sloan Kettering Cancer Center, New York, New York
Obesity and metabolic syndrome correlate with poor oncologic outcome in prostate cancer patients who underwent radical prostatectomy*
Arash Samiei, Allegheny Health Network, Department of Urology, Pittsburgh, Pennsylvania
Plenary Session 5: Metabolomics and Cancer RiskSession Chair: Ralph J. DeBerardinis, University of Texas Southwestern Medical Center, Dallas, Texas 4:45-6:00 p.m.
A metabolomics analysis of body mass index and postmenopausal breast cancer risk Steven C. Moore, National Cancer Institute, Bethesda, Maryland
Subtype-selective metabolic phenotypes in cancerRalph J. Deberardinis
Redox-active metabolites predict clinically relevant nonalcoholic fatty liver disease in the Multiethnic Cohort-Adiposity Phenotype Study (MEC-APS)*
Bruce Kristal, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts
Dinner on Own6:00 p.m.
Monday, Jan. 29
Continental Breakfast 7-8 a.m.
Plenary Sesion 6: Site-Specific Cancers part 2Session Chair: Anna Mae Diehl, Duke University, Durham, North Carolina8-10 a.m.
Obesity and liver cancer: From metabolic alterations to adaptive immunity Michael Karin, University of California San Diego, San Diego, California
Primary liver cancer and NAFLDAnna Mae Diehl
Abdominal versus gluteofemoral obesity and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: The Liver Cancer Pooling Project*
Jessica Petrick, National Cancer Institute, Bethesda, Maryland
Adipokines, visfatin and resistin, promote an invasive liver cancer phenotype* Candance Miethe, Texas State University, San Marcos, Texas
Exploring mechanisms of obesity-driven pancreatic cancer progression in mice*
Mandar Muzumdar, Yale University School of Medicine, New Haven, Connecticut
Plenary Session 7: Spotlight on Circadian Rhythms in the Development of Obesity10:45-11:30 a.m.
Circadian disruption, insulin resistance, and cancer Neil E. Caporaso, National Cancer Institute, Bethesda, Maryland
Sleep duration and circadian components of the sleep/wake cycle and their association with body mass index and eating behaviors in children*Bernard Fuemmeler, Virginia Commonwealth University, Richmond, Virginia
Lunch on Own11:30 a.m.-2 p.m.
Plenary Session 8: Spotlight on the Microbiome in Obesity and CancerRachel Jamison Perry, Yale Medical School, New Haven, Connecticut2-3:30 p.m.
Uncoupling hepatic oxidative phosphorylation reduces tumor growth in a murine colon cancer model
Rachel Jamison Perry
The microbiome and obesity control the tumor microenvironment in the liver and control anti-tumor immunity
Tim F. Greten, National Cancer Institute, Bethesda, Maryland
Nonalcoholic fatty liver disease (NAFLD), an important risk factor for liver cancer, and links to the microbiome in the Multiethnic Cohort-Adiposity Phenotype Study (MEC-APS)* Meredith Hullar, Fred Hutchinson Cancer Research Center, Seattle, Washington
Shifts in gut microbiome populations induced by diet modulate obesity-mediated breast cancer risk*Katherine Cook, Wake Forest University Health Science, Winston Salem, North Carolina
Keynote Speaker4-5 p.m.
Title to be announcedJeffrey M. Friedman, The Rockefeller University, New York, New York
Tuesday, January 30Continental Breakfast 7-8 a.m.
Plenary Session 9: Interventions for Patients Under StudyLewis C. Cantley, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, New York8-10 a.m.
PI 3-Kinase links obesity, insulin resistance, and cancer
Lewis C. Cantley
Title to be announced Kathryn H. Schmitz, Penn State Cancer Institute, Hershey, Pennsylvania
Promoting weight loss in the presurgical setting: What happens to the tumor and the host? Wendy Demark-Wahnefried, University of Alabama Comprehensive Cancer Center, Birmingham, Alabama
Effects of aerobic and resistance exercise on sarcopenic obesity in overweight or obese breast cancer survivors: A randomized controlled trial*
Christina Dieli-Conwright, University of Southern California, Los Angeles, California
Panel Discussion: Prevention of Obesity-Related Cancer at Population LevelFacilitator: Elizabeth A. Platz, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland10:15 a.m.-12 p.m.
Graham A. Colditz, Washington University in St. Louis, St. Louis, Missouri
Closing Remarks12 p.m.